Compare Devon Energy Corp (DVN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Zoetis Inc — how do they compare? Devon Energy Corp trades at $48.26 (market cap $53.81B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Devon Energy Corp is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Zoetis Inc for 70 Days on average.
| DVN | ZTS | |
|---|---|---|
Market Cap | $53.81B | $30.20B |
Volume | 11,556,740 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $52.07 | $147.53 |
52-Week Low | $31.74 | $69.09 |
Typical Hold Time | 136 Days | 70 Days |
Enterprise Value | $64.55B | $37.76B |
Dividend Yield | 2.62% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.92, up 2.17% today, with strong analyst support showing 72% buy ratings and a $62.53 consensus price target. The stock shows bullish technical momentum above key support levels, while fundamentals reveal solid profitability with 16.67% net margins and attractive valuation at 10.63 P/E. Recent activist pressure from Toms Capital for strategic alternatives and potential asset sales with BP creates near-term catalysts.
DVN presents compelling value with upside potential to analyst targets, though faces execution risks on asset sales and oil price volatility. The company's improving cash flow generation and Permian Basin focus support the bullish case, but investors should monitor activist developments and energy market conditions closely.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
